Court Opinion

ID: 8413955
Source: CourtListenerOpinion
Date Created: 2022-11-02 20:43:08.754437+00
Date Added: 2024-06-11T16:48:06.259580
License: Public Domain

Opinion by Judge GRABER; per curiam Concurrence.
OPINION
GRABER, Circuit Judge:
Plaintiff Animal Legal Defense Fund filed a Freedom of Information Act (“FOIA”) request with the Food and Drug Administration (“FDA”) regarding egg-production farms in Texas. The FDA released almost 400 pages of documents but redacted data regarding total hen population, number of hen houses, number of floors per house, number of cage rows per house, number of cage tiers per house, and number of birds- per cage for each farm in question.- Plaintiff filed this FOIA action seeking to compel the FDA to release the redacted data. The district court ordered the release of information regarding the number of birds per cage at each farm. But the court held on summary judgment that, under FOIA Exemption 4, the FDA properly withheld the other categories of information because its release was “likely to cause substantial competitive harm.” See 5 U.S.C. § 552(b)(4). • We affirm.
FACTUAL AND PROCEDURAL HISTORY
In late 2011, Plaintiff submitted a FOIA request to the FDA that sought the following:
• All FDA documents since April 26, 2011, relating to egg safety in Texas, egg production in Texas, or egg-production facilities in Texas;
• All FDA communications with Texas state government agencies since April 26, 2011, relating to egg safety, egg production, or egg-production facilities; and
• All communications between the FDA and egg producers in Texas since April 26, 2011.
The FDA released records related to inspections of eleven chicken egg-production facilities; one quail egg-production facility and food manufacturer; one food warehouse; and one food distribution center. But redactions appeared on 277 of the 398 pages that the FDA produced.
*1106■ Plaintiff filed a complaint for injunctive and declaratory relief under FOIA, 5 U.S.C. § 552, seeking to compel the production of the following information regarding inspected egg-production facilities: total hen population; number of hen houses; number of floors per house; number of cage rows per house; number of cage tiers per house; and number of birds per cage. The FDA moved for summary judgment on the ground that FOIA Exemption 4— which applies to “trade secrets and commercial or financial information obtained from a person and privileged or confidential,” id, -§ 552(b)(4) — protected the redacted data. In support of its motion, the FDA submitted several declarations from experts who stated that releasing the requested information would enable competitors to learn a given egg producer’s production rate, which in turn would allow the competitors to undercut the egg producer’s prices and lure away customers. Plaintiff filed a cross-motion for summary judgment, supported by its own declarations from an economist and a food industry consultant. Those experts attested that releasing the withheld information would not facilitate competitive underbidding.
Plaintiff also asked to suspend briefing of FDA’s summary judgment motion in order to permit discovery directed to whether the information sought was publicly available. The district court denied that request because, among other things, Plaintiff had not shown that the discovery it 'sought “is essential to litigating the motion for summary judgment.”
After briefing and oral argument, the district court granted in part and denied in part both parties’ summary judgment motions. The district court held that the FDA had fallen short of showing how releasing the number of birds per cage would “threaten any competitive harm” and ordered disclosure of that information. But the court concluded that the FDA had established that the release of the other five categories of redacted information— total hen population, number of hen houses, number of floors per house, number of cage rows per house, and number of cage tiers per house — was likely to result in substantial competitive harm due to underbidding.
Plaintiff timely appeals the court’s grant of summary judgment in favor of the FDA on the redaction of those five categories of information, as well as the denial of third-party discovery.
STANDARDS OF REVIEW
“Our review of a grant of summary judgment in a FOIA case ... is slightly different than for other types of cases....” Yonemoto v. Dep’t of Veterans Affairs, 686 F.3d 681, 688 (9th Cir.2012). We first determine, de novo, whether an adequate factual basis supports the district court’s decision. Id. “Whether a particular set of documents gives the court an adequate ’ factual basis for its decision is a question of law that the court reviews de novo.’’ Lion Raisins, Inc. v. U.S. Dep’t of Agric, 354 F.3d 1072, 1078 (9th Cir.2004). If no adequate. factual basis exists, the case must be remanded for further- development of the record. Yonemoto, 686 F.3d at 688.
If such a factual basis exists, we next treat the judgment as “if it were a bench trial,” so that “the district court’s conclusions of fact are reviewed for clear error.” Id. (internal quotation marks omitted). On the other hand, “legal rulings, including [the district court’s] decision that a particular exemption applies, are reviewed de novo.” Id. As we noted in Lion Raisins, whether withheld information could be used by a food producer to undercut competitors is a determination that is “grounded in ... findings of fact.” *1107354 F.3d at 1078. Therefore, if we determine that the district court had an adequate factual basis for reaching, its decision, we must review for clear error the district court’s conclusion that releasing the redacted information likely would cause substantial competitive harm. Id.
We review for abuse of discretion a district court’s denial of discovery before ruling on summary judgment. U.S. Cellular Inv. Co. of L.A., Inc. v. GTE Mobilnet, Inc., 281 F.3d 929, 934 (9th Cir.2002).
DISCUSSION
A. Disclosure Under FOIA
“Disclosure, not secrecy, is the dominant objective of FOIA.” Shannahan v. IRS, 672 F.3d 1142, 1148 (9th Cir.2012) (internal quotation marks • and brackets omitted). “We construe narrowly FOIA’s nine exemptions.” Id. The FDA relies on Exemption 4, 5 U.S.C. § 552(b)(4); “which is available to prevent disclosure of (1) commercial and financial ■ information, (2) obtained from a person or by the government, (3) that is privileged or confidential.” 1 GC Micro Corp. v. Def. Logistics Agency, 33 F.3d 1109, 1112 (9th Cir.1994). Commercial information qualifies as “confidential” when disclosure is “likely .... to cause substantial harm to the competitive position of the person from whom the information was obtained.” Id. 1112-13.(citing Nat’l Parks & Conservation Ass’n v. Morton, 498 F.2d 765, 770 (D.C.Cir.1974)).
B. Adequate Factual Basis
As noted above, we first must determine whether the district court had an adequate factual basis to reach its decision. Lion Raisins, 354 F.3d at 1079, “In making this determination, we may rely solely on government affidavits so long as the affiants are knowledgeable about the information sought and the affidavits are detailed enough to allow the court.to make an independent assessment of the government’s claim.” Kowack v. U.S. Forest Serv., 766 F.3d 1130, 1132 (9th Cir.2014) (internal quotation'marks omitted). That threshold is met here;
Several of the declarations by the FDA’s experts stated that the egg-production industry was “highly” or “extremely competitive.” One emphasized that “anything that changes costs by even a penny can make a huge difference.” According to the experts, the redacted information was likely to cause substantial competitive harm because the competitors of the egg producers in question could use the information to 'form accurate estimates of each farm’s or producer’s rate of production and use those estimates to Underbid. For example, one declarant stated that, once a competitor knows the production rate at an egg farm, the competitor is able to “enter the farm’s regional market arid offer to produce the same number of eggs per day for a lower price or a greater number of eggs per day for the same price and thereby lure away the farm’s custom^ ers.” As in Lion Raisins, 354 F.3d at 1079-80, the declarations in this case established an adequate factual basis. The declarations provided the district court with the identity of the information sought and the claimed exemption, and provided the necessary detail about the specific competitive harm that could arise from the release of the redacted information. See *1108also Bowen v. FDA, 925 F.2d 1225, 1227-28 (9th Cir.1991) (holding that government affidavits that described the documents withheld, the statutory exemptions claimed, and the specific reasons for the agency’s withholding provided an adequate factual basis for application of Exemption 4).
O.' Review of District Court’s Analysis for Clear Error ■ .
We next must decide whether the district court clearly erred in determining that the redacted information fell within Exemption 4’s protection. “[The clear error] standard is significantly deferential, and we will accept the lower court’s findings of fact unless we are left -with the definite and firm conviction that a mistake has been committed.” Lentini v. Cal. Ctr. for the Arts, 370 F.3d 837, 848-49 (9th Cir.2004) (internal quotation marks omitted).
“An agency seeking to withhold information under an exemption to FOIA has the burden of proving that the information falls under the claimed exemption.” GC Micro Corp., 33 F.3d at 1113. “While conclusory and generalized allegations of competitive harm are insufficient to show that requested information is ‘confidential,’ ” the government need not show that releasing the documents would cause “actual competitive harm.” Id. “Rather, the government need only show that there is (1) actual competition in the relevant market, and (2) a likelihood of substantial competitive injury if the information were released.” Lion Raisins, 354 F.3d at 1079.
Plaintiff does not contest that there is actual competition in the egg-production market, and, it also concedes that the redacted information could be used to estimate an egg farm’s production capacity. The parties disagree, however, as to whether releasing the redacted information would likely cause “substantial competitive harm” to the affected egg producers and farmers.
Whether or not releasing the requested data would create a likelihood of substantial competitive harm was subject to dispute. But, on this record, the district court.did not clearly err in finding that disclosure of the information was likely to cause commercial undercutting. The FDA provided declarations that explained how the information would facilitate accurate estimates of a farm’s egg-production capacities and how those estimates could facilitate undercutting. For example, one declarant explained that the egg-production industry has a “tight profit margin”; industry experts estimate that an average profit is approximately 6.7 cents per dozen eggs sold. If a national egg producer were able to determine the production rates of its smaller competitors, it could direct its resources toward that market; and if the national producer were able to offer lower prices, “even a penny can make a huge difference” in the local company’s ability to keep its customers.
Although the information sought may not provide a national egg producer with every piece of information that it would consider before entering a new market, knowing the production capacity of potential competitors could make the decision of whether or not to enter a competitor’s market easier. By becoming aware of potential limitations in its competitors’ production capabilities, a national producer could decide to focus all its resources on egg markets in which it could out-produce local competitors — whether in terms of efficiency, price, or total quantity. See Lion Raisins, 354 F.3d at 1081 (holding that releasing information that allows a raisin farmer to “infer the volume of its competitors’ raisin sales” could facilitate undercut*1109ting and, therefore, create a likelihood of substantial competitive harm).
Plaintiff submitted its own declarations, which asserted that the production information it seeks is insufficient to affect the market. Nevertheless, under our special standard of review for FOIA cases, and in view of the extensive FDA affidavits, we see no clear error. The incomplete data could allow egg producers to make more accurate — if imperfect — estimates of their competitors’ production capabilities and sales than they could without the redacted information. Due to the competitiveness of. the egg-production ■ industry, where “even a penny can make a huge, difference,” even a slight upgrade in the accuracy of projections might have a large effect on competition. Although the information may not afford egg producers their , competitors’ exact profit-per-egg statistics, the FDA need only establish, as the district court correctly noted, “a likelihood of substantial competitive harm, not a certainty.”2
D. Third-Party Discovery
The district court did not abuse its discretion by denying third-party discovery. In response to a summary judgment motion, a non-moving party may obtain relief pursuant to Federal Rule of Civil Procedure 56(d) if it “shows by affidavit or declaration that, for specified reasons, it cannot present facts essential to justify its opposition.” A party' seeking further discovery must show that there is “some basis for believing that the information sought actually exists.” Blough v. Holland Realty, Inc., 574 F.3d 1084, 1091 n. 5 (9th Cir.2009) (internal quotation marks omitted). Further, a party seeking discovery must show that it lacks the “essential facts” to resist the summary judgment motion. Cal. Union Ins. Co. v. Am. Diversified Sav. Bank, 914 F.2d 1271, 1278 (9th Cir.1990).
Plaintiff here sought additional discovery to show that the sought-after information was already publicly available. The district court ruled that the evidence Plaintiff sought was not sufficiently similar to’ the information requested through discovery; Plaintiffs request was grounded in speculation; and allowing discovery of “an individual farm’s egg production could improperly give Plaintiff information that it could not obtain through its FOIA request.” That ruling fell within the district court’s range of discretion.
AFFIRMED.

. Tide 5 U.S.C. § 552(b)(4) specifically provides:
This section [requiring disclosure of information] does not apply to matters that are—
(4) trade secrets and commercial or financial information obtained from a person and privileged or confidential^]

. We are likewise unpersuaded by Plaintiff's argument that the redacted information is already publicly available and, therefore, cannot be considered likely to cause substantial competitive harm. The sought-after data is more detailed and more specific than anything currently available in the public domain. For that reason, Plaintiff’s argument fails. See Wolf v. CIA, 473 F.3d 370, 378 (D.C.Cir.2007) ("Prior disclosure of similar information does not suffice; instead, the specific information sought by the plaintiff must already be in the public domain by official disclosure.”); Fitzgibbon v. CIA, 911 F.2d 755, 765 (D.C.Cir.1990) ("[T]he information requested must be as specific as the information previously released,”).